Moderna to Pay $950M to Settle Long Running COVID Patent Litigation with Genevant, Arbutus

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud.

Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roivant subsidiary Genevant and infectious disease biotech Arbutus in 2022, alleging Moderna infringed their patents with the lipid nanoparticle (LNP) delivery technology in its blockbuster shot.

Read more at Fierce Pharma